Categories AlphaGraphs, Earnings, Health Care

Traxde Health beats on Q3 revenue estimate

Company adds over 250 registered members during the quarter

Trxade Health Inc (NASDAQ: MEDS) on Monday posted third-quarter revenues of $2.6 million, down year-over-over as a result of non-recurring PPE sales. However, this was higher than what analysts had anticipated.

For Q3, the company posted a net loss of $0.16 per share, which was wider than the street expectation by 3 cents.  

MEDS shares were trading flat during the aftermarket hours on Monday. The stock has dipped 14% over the past six months.

Trxade Health Q3 2021 earnings

CEO Suren Ajjarapu said in a statement, “We are focusing new strategic partnerships to drive forward our core business while diversifying our revenue base and leveraging our existing strengths through Bonum Health. Taken as a whole, we believe we are building an incredibly compelling healthcare ecosystem – allowing consumers access to affordable healthcare while building an exciting value proposition for our shareholders.”

In the third quarter, the Tampa, Florida-based firm added about 250 new registered members to its network. The company now has over 12,950 registered pharmacy members.

Trxade, which brings together independent pharmacies under one umbrella through its web-based purchasing platform, is present in all 50 states and is rapidly adding pharmacies to its network.

Prior Performance

  • Trxade Health Q2 2021 earnings
  • Trxade Q1 2021 earnings
  • Trxade Q4 2020 earnings
  • Trxade Group Q3 2020 earnings

For more insights into Trxade Group, access the latest research summary.

Most Popular

Shopify (SHOP): This recession-proof stock looks unstoppable. Here’s why

The virus-related movement restrictions have had a complementary effect on the business of Shopify Inc. (NYSE: SHOP), which was already thriving on the widespread cloud adoption and digital shift. The

IPO: Here are the things to know about Fresh Grapes’ market debut

There has been a spurt in the number of food and beverages companies going public lately, but many of them failed to perform as expected in the stock market. Fresh

Hormel Foods (HRL) fine-tunes biz strategy to beat challenges. Is the stock a buy?

For consumer staples companies, rising inflation is probably turning into a bigger challenge than the virus-induced supply chain disruption and store closures. After bettering its position since the early months

Add Comment
Viewing Highlight